Background: Glioblastoma is a grade IV astrocytoma with an average survival span for patients of 18 months after initial diagnosis and no standard treatment protocol is available. Therefore, there is a need to search for novel approaches to target glioblastoma.

Objectives: This review intends to capture the role of immunoglobulin-M in cancer, more specifically in glioblastoma multiforme (GBM), and to compile the latest developments and immunological pathways relevant to glioblastoma.

Methods: Information on glioblastoma, cancer microenvironment, cancer therapeutics, and how to improve the scenario were obtained from scientific literature databases such as Pubmed, Medline, Google Scholar, Science Direct, Springer, Wiley online library, and some data was harvested from regulatory and compliance databases such as clinicaltrials.gov, FDA database, and WHO Globocan.

Results and Conclusion: Currently, only a limited number of therapies are approved for GBM, and no standard care is in place in case of disease relapse, necessitating a possible broader perspective in looking at the disease and its underlying mechanisms.

背景：胶质母细胞瘤是一种 IV 级星形细胞瘤，患者在初始诊断后的平均生存期为 18 个月，并且没有可用的标准治疗方案。因此，需要寻找靶向胶质母细胞瘤的新方法。

目的：本综述旨在捕捉免疫球蛋白-M 在癌症中的作用，更具体地说是在多形性胶质母细胞瘤 (GBM) 中的作用，并汇编与胶质母细胞瘤相关的最新进展和免疫学途径。

方法：从 Pubmed、Medline、Google Scholar、Science Direct、Springer、Wiley 在线图书馆等科学文献数据库中获取有关胶质母细胞瘤、癌症微环境、癌症治疗方法以及如何改进方案的信息，并从监管和合规性数据库，例如临床试验.gov、FDA 数据库和 WHO Globocan。

结果和结论：目前，GBM 的治疗方法数量有限，并且没有针对疾病复发的标准护理，因此需要从更广泛的角度看待疾病及其潜在机制。